Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Down 12.2% in February

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 14,400 shares, a drop of 12.2% from the January 31st total of 16,400 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily volume of 45,100 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Cocrystal Pharma in a research note on Wednesday, January 22nd.

Cocrystal Pharma Price Performance

NASDAQ:COCP traded up $0.05 during midday trading on Thursday, reaching $1.77. 5,466 shares of the company traded hands, compared to its average volume of 31,197. The firm has a market capitalization of $18.00 million, a price-to-earnings ratio of -0.96 and a beta of 2.35. The company has a fifty day moving average price of $2.05 and a 200 day moving average price of $1.96. Cocrystal Pharma has a twelve month low of $1.35 and a twelve month high of $3.26.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.